<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> and impaired beta-cell function are primary defects that occur early in the course of development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> leads to <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo> in order to maintain <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance </plain></SENT>
<SENT sid="2" pm="."><plain>In most cases of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0006279'>beta-cell dysfunction</z:hpo> develops subsequent to the development of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, and it is not until such <z:hpo ids='HP_0006279'>beta-cell dysfunction</z:hpo> develops that any abnormality in <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance is seen </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> is a primary defect in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>The risk of <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> is significantly increased in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular disease</z:e> causes 80% of <z:hpo ids='HP_0000001'>all</z:hpo> diabetic mortality, and in 75% of those cases, it is a result of <z:hpo ids='HP_0004929'>coronary atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>These points provide a rationale for early and aggressive management of cardiovascular risk in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="50864">Thiazolidinediones</z:chebi> represent an effective tool for targeting some features of this increased risk as they decrease <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and can prevent and/or delay <z:mp ids='MP_0002055'>diabetes</z:mp> progression </plain></SENT>
</text></document>